The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

Stella Maris Garay1 · Ruben Cuttica2 · Maria Martha Katsicas3 · Graciela Espada4 · Carmen De Cunto5 · Mariana Fabi1 · Jimena Gomez Sosa2 · Ricardo Russo3 · María de los Angeles Britos5 · Alessandro Consolaro6,7 · Francesca Bovis6 · Nicolino Ruperto6 · For the Paediatric Rheumatology International Trials Organisation (PRINTO)

Received: 22 December 2017 / Accepted: 11 January 2018
© The Author(s) 2018. This article is an open access publication

Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Argentinian Spanish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and discriminant validity). A total of 373 JIA patients (23.1% systemic, 30.8% oligoarticular, 28.1% RF negative polyarthritis, 18% other categories) and 100 healthy children were enrolled in five centres. The JAMAR components discriminated well healthy subjects from JIA patients. Notably, there was no significant difference between healthy subjects and their affected peers in the school-related item. All JAMAR components revealed good psychometric performances. In conclusion, the Argentinian Spanish version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.

Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR

Introduction
The aim of the present study is to cross-culturally adapt and validate the Argentinian Spanish parent and patient versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) [1] in patients with juvenile idiopathic arthritis (JIA). The JAMAR assesses the most relevant parent/patient reported outcomes in JIA, including overall well-being, functional status, health-related quality of life (HRQoL), pain, morning stiffness, disease activity/status/course, articular and extra-articular involvement, drug-related side effects/compliance and satisfaction with illness outcome.

This project was part of a larger multinational study conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) [2] aimed to evaluate the Epidemiology, Outcome and Treatment of Childhood Arthritis (EPOCA) in different geographic areas [3].

We report herein the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Argentinian Spanish language.
Materials and methods

The methodology employed has been described in detail in the introductory paper of the supplement [4]. In brief, it was a cross-sectional study of JIA children, classified according to the ILAR criteria [5, 6] and enrolled from June 2012 to December 2014. Children were recruited after Ethics Committee approval and consent from at least one parent.

The JAMAR

The JAMAR [1] includes the following 15 sections:

1. Assessment of physical function (PF) using 15 items in which the ability of the child to perform each task is scored as follows: 0 = without difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do and not applicable if it was not possible to answer the question or the patient was unable to perform the task due to their young age or to reasons other than JIA. The total PF score ranges from 0 to 45 and has three components: PF-lower limbs (PF-LL), PF-hand and wrist (PF-HW) and PF-upper segment (PF-US) each scoring from 0 to 15 [7]. Higher scores indicating higher degree of disability [8–10];
2. rating of the intensity of the patient’s pain on a 21-numbered circle visual analogue scale (VAS) [11];
3. assessment of the presence of joint pain or swelling (present/absent for each joint);
4. assessment of morning stiffness (present/absent);
5. assessment of extra-articular symptoms (fever and rash) (present/absent);
6. rating of the level of disease activity on a 21-circle VAS;
7. rating of disease status at the time of the visit (categorical scale);
8. rating of disease course from previous visit (categorical scale);
9. checklist of the medications the patient is taking (list of choices);
10. checklist of side effects of medications;
11. report of difficulties with medication administration (list of items);
12. report of school/university/work problems caused by the disease (list of items);
13. assessment of HRQoL, through the Physical Health (PhH), and Psychosocial Health (PsH) subscales (five items each) and a total score. The four-point Likert response, referring to the prior month, are ‘never’ (score = 0), ‘sometimes’ (score = 1), ‘most of the time’ (score = 2) and ‘all the time’ (score = 3). A ‘not assessable’ column was included in the parent version of the questionnaire to designate questions that cannot be answered because of developmental immaturity. The total HRQoL score ranges from 0 to 30, with higher scores indicating worse HRQoL. A separate score for PhH and PsH (range 0–15) can be calculated [12–14];
14. rating of the patient’s overall well-being on a 21-numbered circle VAS;
15. a question about satisfaction with the outcome of the illness (yes/no) [15].

The JAMAR is available in three versions, one for parent proxy-report (child’s age 2–18), one for child self-report, with the suggested age range of 7–18 years, and one for adults.

Cross cultural adaptation and validation

The process of cross-cultural adaptation was conducted according to international guidelines with 2–3 forward and backward translations. In those countries for which the translation of JAMAR had been already cross-cultural adapted in a similar language (i.e. Spanish in South American countries), only the probe technique was performed. Reading comprehension and understanding of the translated questionnaires were tested in a probe sample of 10 JIA parents and 10 patients.

Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents.

The statistical validation phase explored the descriptive statistics and the psychometric issues [16]. In particular, we evaluated the following validity components: the first Likert assumption [mean and standard deviation (SD) equivalence]; the second Likert assumption or equal items–scale correlations (Pearson $r$: all items within a scale should contribute equally to the total score); third Likert assumption (item internal consistency or linearity for which each item of a scale should be linearly related to the total score that is 90% of the items should have Pearson $r \geq 0.4$); floor/ceiling effects (frequency of items at lower and higher extremes of the scales, respectively); internal consistency, measured by the Cronbach’s alpha, interscale correlation (the correlation between two scales should be lower than their reliability coefficients, as measured by Cronbach’s alpha); test–retest reliability or intraclass correlation coefficient (reproducibility of the JAMAR repeated after 1 or 2 weeks); and construct validity in its two components: the convergent or external validity which examines the correlation of the JAMAR subscales with the 6 JIA core set variables, with the addition of the parent assessment of disease activity and pain by the
Spearman’s correlation coefficients (r) [17] and the discriminant validity, which assesses whether the JAMAR discriminates between the different JIA categories and healthy children [18].

Quantitative data were reported as medians with 1st and 3rd quartiles and categorical data as absolute frequencies and percentages.

The complete Argentinian Spanish parent and patient versions of the JAMAR are available upon request to PRINTO.

Results

Cross cultural adaptation

The Argentinian Spanish JAMAR was fully cross-culturally adapted from the standard English version with two forward and two backward translations with a concordance for 118/123 (95.9%) translations lines for the parent version and 116/120 (96.7%) lines for the child version. Of the 123 lines in the parent version of the JAMAR, 115 (93.5%) were understood by at least 80% of the 10 parents tested (median = 100%; range 50–100%). In the patient version of the JAMAR, 119/120 (99.2%) lines were understood by at least 80% of the children (median = 100%; range 60–100%). Lines 11, 64, 65, 83, 84, 87, 88, 96 of the parent JAMAR and line 62 of the child JAMAR were modified according to parents’ and patients’ suggestions.

Demographic and clinical characteristics of the subjects

A total of 373 JIA patients and 100 healthy children (total of 473 subjects), were enrolled at five paediatric rheumatology centres.

In the 373 JIA subjects, the JIA categories were 23.1% with systemic arthritis, 30.8% with oligoarthritis, 28.1% with RF negative polyarthritis, 9.9% with RF positive polyarthritis, 1.3% with psoriatic arthritis, 6.2% with enthesitis related arthritis and 0.5% with undifferentiated arthritis (Table 1).

A total of 472/473 (99.8%) subjects had the parent version of the JAMAR completed by a parent (373 from parents of JIA patients and 99 from parents of healthy children). The JAMAR was completed by 434/472 (91.9%) mothers and 38/472 (8.1%) fathers. The child version of the JAMAR was completed by 395/473 (83.5%) children age 6.2 or older. Also patients younger than 7 years old, capable to assess their personal condition and able to read and write, were asked to fill in the patient version of the questionnaire.

Discriminant validity

The JAMAR results are presented in Table 1, including the scores [median (1st–3rd quartile)] obtained for the PF, the PhH, the PsH subscales and total score of the HRQoL scales. The JAMAR components discriminated well between healthy subjects and JIA patients.

In summary, the JAMAR revealed that JIA patients had a greater level of disability and pain, as well as a lower HRQoL than their healthy peers. However, there was no significant difference between healthy subjects and their affected peers in the school-related item.

Psychometric issues

The main psychometric properties of both parent and child versions of the JAMAR are reported in Table 2. The following results section refers mainly to the parent’s version findings, unless otherwise specified.

Descriptive statistics (first Likert assumption)

There were no missing results for all JAMAR items, since data were collected through a web-based system that did not allow to skip answers or input null values. The response pattern for both PF and HRQoL was positively skewed toward normal functional ability and normal HRQoL. All response choices were used for the different HRQoL items, whereas a reduced number of response choices were used for PF items 5.

The mean and SD of the items within a scale were roughly equivalent for the PF and for the HRQoL items (data not shown). The median number of items marked as not applicable was 1% (0–1%) for the PF and 3.5% (2–6%) for the HRQoL.

Floor and ceiling effect

The median floor effect was 85% (83.6–90.9%) for the PF items, 74% (64.3–77.7%) for the HRQoL PhH items, and 74.3% (66.8–75.1%) for the HRQoL PsH items. The median ceiling effect was 0.5% (0.5–1.6%) for the PF items, 1.3% (1.1–2.9%) for the HRQoL PhH items, and 1.3% (1.1–2.6%) for the HRQoL PsH items. The median floor effect was 50.1% for the pain VAS, 47.4% for the disease activity VAS and 50.9% for the well-being VAS. The median ceiling effect was 0.5% for the pain VAS, 1.3% for the disease activity VAS and 0.8% for the well-being VAS.
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 373 JIA patients

|                      | Systemic Oligoarthritis | RF – poly-arthritis | RF+poly-arthritis | Psoriatic arthritis | Enthesitis-related arthritis | Undifferentiated arthritis | All JIA patients | Healthy |
|----------------------|--------------------------|---------------------|-------------------|--------------------|-----------------------------|---------------------------|------------------|---------|
| N                    | 86                       | 115                 | 37                | 5                  | 23                          | 2                          | 373              | 100     |
| Female               | 53 (61.6%)               | 84 (73%)            | 77 (73.3%)        | 36 (97.3%)         | 3 (13%)                     | 2 (100%)                  | 258 (69.2%)      | 48 (48%)** |
| Age at visit         | 11 (7.6–13.1)            | 11.1 (7.7–13.7)     | 13.2 (10.6–15.7)  | 14.7 (12.8–16.1)   | 12.7 (10.7–15.1)            | 14.4 (12.5–16.7)          | 9.2 (9.2–9.3)    | 12.5 (9.1–15.1)** |
| Age at onset         | 3.8 (2.5–6.5)            | 3.6 (2.1–7)         | 6.9 (3.7–10)      | 8.8 (6.5–12.8)     | 5.7 (4.6–10.1)              | 10.1 (9–11.9)            | 4.5 (2.7–6.2)    | 5.7 (2.8–9.7)*  |
| Disease duration     | 5.8 (3.3–8.3)            | 5 (1.8–8)           | 6 (2.9–8.6)       | 4.4 (2.1–7.1)      | 6.1 (5.9–6.9)               | 3.1 (2.3–6.7)            | 4.8 (2.9–6.6)    | 5.4 (2.5–8)    |
| ESR                  | 8.5 (4–22)               | 11 (7–21)           | 18 (10–30)        | 16 (12–40)         | 16 (8–18)                   | 12.5 (8.5–36)           | 28 (6–50)        | 13 (7–27)*   |
| MD VAS (0–10 cm)  | 0 (0–2)                  | 0 (0–1)             | 0 (0–2)           | 1 (0–3)            | 1.5 (1–2)                   | 1.5 (0–3)                | 3 (3–3)          | 0 (0–2)*     |
| No. swollen joints   | 0 (0–5)                  | 0 (0–1)             | 1 (0–4)           | 1 (0–10)           | 1 (0–5)                     | 1 (0–4)                  | 4 (2–6)          | 0 (0–3)*     |
| No. joints with pain | 0 (0–0)                  | 0 (0–0)             | 0 (0–1)           | 0 (0–2)            | 0 (0–0)                     | 0 (0–0)                  | 1 (0–2)          | 0 (0–1)*     |
| No. joints with LOM | 1.5 (0–7)                | 1 (0–1)             | 2 (0–5)           | 1 (0–3)            | 2 (0–4)                     | 3 (2–4)                  | 1 (0–3)*         |           |
| No. active joints    | 0 (0–6)                  | 0 (0–1)             | 1 (0–4)           | 1 (0–10)           | 1 (0–5)                     | 4 (2–6)                  | 0 (0–3)*         |           |
| Active systemic features | 8 (9.3%)               | 0 (0%)              | 0 (0%)           | 0 (0%)            | 0 (0%)                       | 0 (0%)                   | 8 (2.1%)         |           |
| ANA status           | 1 (1.2%)                 | 34 (29.6%)          | 10 (9.5%)         | 8 (21.6%)          | 1 (20%)                     | 0 (0%)                   | 54 (14.5%)       |           |
| Uveitis              | 1/84 (1.2%)              | 23/114 (20.2%)      | 1/102 (1%)        | 0 (0%)            | 0 (0%)                       | 3/22 (13.6%)             | 0 (0%)          | 28/365 (7.7%) |
| PF Total Score       | 0 (0–3)                  | 0 (0–2)             | 0 (0–4)           | 2 (0–7)            | 0 (0–1)                     | 2 (0–4)                  | 4.5 (4–5)       | 0 (0–3)*     |
| Pain VAS             | 0 (0–1)                  | 0 (0–2.5)           | 0.5 (0–1.5)       | 1 (0–2.5)          | 1 (1–2)                     | 0.5 (0–4)               | 3 (3–3)         | 0 (0–2)*     |
| Disease Activity VAS | 0 (0–2)                  | 0 (0–2.5)           | 0.5 (0–2.5)       | 0.5 (0–3)          | 3 (1–3)                     | 1.5 (0–4)               | 3.5 (3–4)       | 0.5 (0–2.5)* |
| Well-being VAS       | 0 (0–1)                  | 0 (0–2.5)           | 0.5 (0–2.5)       | 1 (0–2.5)          | 0.5 (0–3)                   | 2.5 (0.5–3.5)           | 4 (3–5)         | 0.25 (0–2.5)* |
| HRQoL PsH            | 1 (0–3)                  | 1 (0–3)             | 1 (0–3)           | 1 (0–3)            | 2 (1–3)                     | 4.5 (2–7)               | 1 (0–3)*         | 0 (0–4)     |
| HRQoL Ph              | 1 (0–3)                  | 1 (0–3)             | 1 (0–3)           | 1 (0–3)            | 2 (0–4)                     | 0.5 (0–1)               | 1 (0–3)         | 0 (0–1)*     |
| HRQoL Total Score    | 2 (0–6)                  | 2 (0–4)             | 2 (0–6)           | 3 (0–8)            | 1 (1–1)                     | 5 (2–7)                 | 5 (3–7)         | 2 (0–6)     |
| Pain/swell. in > 1 joint | 32 (37.2%)              | 48 (41.7%)          | 54 (51.4%)        | 24 (64.9%)         | 4 (80%)                      | 14 (60.9%)               | 2 (100%)        | 178 (47.7%)* |
| Morning stiffness > 15 min | 10 (11.6%)              | 9 (7.8%)            | 20 (19%)          | 10 (27%)           | 0 (0%)                      | 4 (17.4%)               | 0 (0%)          | 53 (14.2%) |
| Subjective remission | 31 (36%)                 | 38 (33%)            | 45 (42.9%)        | 21 (56.8%)         | 4 (80%)                      | 15 (65.2%)               | 2 (100%)        | 156 (41.8%)** |
| In treatment         | 76 (88.4%)               | 87 (75.7%)          | 90 (85.7%)        | 34 (91.9%)         | 5 (100%)                     | 22 (95.7%)               | 2 (100%)        | 316 (84.7%) |
| Reporting side effects | 16/76 (21.1%)           | 12/87 (13.8%)       | 20/90 (22.2%)     | 8/34 (23.5%)       | 0 (0%)                      | 6/22 (27.3%)            | 1 (50%)         | 63/316 (19.9%) |
| Taking medication regularly | 75/76 (98.7%)         | 80/87 (92%)         | 82/90 (91.1%)     | 31/34 (91.2%)      | 5 (100%)                     | 20/22 (90.9%)           | 2 (100%)        | 295/316 (93.4%) |
| With problems attending school | 7/69 (10.1%)            | 0 (0%)              | 1/76 (1.3%)       | 2/27 (7.4%)        | 0 (0%)                      | 1/18 (5.6%)             | 0 (0%)          | 11/284 (3.9%) |
| Satisfied with disease outcome | 69 (80.2%)             | 85 (73.9%)          | 83 (79%)         | 29 (78.4%)         | 3 (60%)                      | 16 (69.6%)               | 1 (50%)         | 286 (76.7%) |

Data related to the JAMAR refers to the 373 JIA patients and to the 99 healthy subjects for whom the questionnaire has been completed by the parents.

*JAMAR* Juvenile Arthritis Multidimensional Assessment Report, *ESR* erythrocyte sedimentation rate, *MD* Medical Doctor, *VAS* visual analogue scale (score 0–10; 0 = no activity, 10 = maximum activity), *LOM* limitation of motion, *ANA* anti-nuclear antibodies, *PF* physical function (total score ranges from 0 to 45), *HRQoL* health-related quality of life (total score ranges from 0 to 30), *PsH* physical health (total score ranges from 0 to 15), *PsH* psychosocial health (total score ranges from 0 to 15).

*p* values refers to the comparison of the different JIA categories or to JIA versus healthy. *p* < 0.05, **p* < 0.001, *p* < 0.0001.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR

| Missing values (1st–3rd quartiles) | Parent \(N = 373/472\) | Child \(N = 321/395\) |
|-----------------------------------|--------------------------|----------------------|
| Response pattern                  | No missing values        | No missing values    |
| Floor effect, median              | PF and HRQoL positively skewed | PF and HRQoL positively skewed |
|                                   | PF                       | 85.0%                | 87.2%                |
|                                   | HRQoL PhH                | 74.0%                | 72.9%                |
|                                   | HRQoL PsH                | 74.3%                | 73.2%                |
|                                   | Pain VAS                 | 50.1%                | 49.2%                |
|                                   | Disease activity VAS     | 47.4%                | 51.1%                |
|                                   | Well-being VAS           | 50.9%                | 54.5%                |
| Ceiling effect, median            | PF                       | 0.5%                 | 0.3%                 |
|                                   | HRQoL PhH                | 1.3%                 | 1.9%                 |
|                                   | HRQoL PsH                | 1.3%                 | 2.2%                 |
|                                   | Pain VAS                 | 0.5%                 | 0.9%                 |
|                                   | Disease activity VAS     | 1.3%                 | 0.9%                 |
|                                   | Well-being VAS           | 0.8%                 | 0.9%                 |
| Items with equivalent item–scale correlation | 93% for PF, 100% for HRQoL | 87% for PF, 90% for HRQoL |
| Items with items–scale correlation ≥ 0.4 | 100% for PF, 100% for HRQoL | 100% for PF, 100% for HRQoL |
| Cronbach's alpha                  | PF-LL                    | 0.92                 | 0.87                 |
|                                   | PF-HW                    | 0.91                 | 0.85                 |
|                                   | PF-US                    | 0.88                 | 0.85                 |
|                                   | HRQoL PhH                | 0.83                 | 0.82                 |
|                                   | HRQoL PsH                | 0.79                 | 0.82                 |
| Items with item–scale correlation lower than the Cronbach's alpha | 100% for PF, 100% for HRQoL | 100% for PF, 100% for HRQoL |
| Test–retest intraclass correlation | PF total score           | 0.97                 | 0.98                 |
|                                   | HRQoL PhH                | 0.88                 | 0.97                 |
|                                   | HRQoL PsH                | 0.79                 | 0.90                 |
| Spearman correlation with JIA core-set variables, median | PF                       | 0.6                  | 0.6                  |
|                                   | HRQoL PhH                | 0.6                  | 0.6                  |
|                                   | HRQoL PsH                | 0.3                  | 0.3                  |
|                                   | Pain VAS                 | 0.5                  | 0.5                  |
|                                   | Disease activity VAS     | 0.5                  | 0.5                  |
|                                   | Well-being VAS           | 0.5                  | 0.5                  |

**JAMAR** Juvenile Arthritis Multidimensional Assessment Report, **JIA** juvenile idiopathic arthritis, **VAS** visual analogue scale, **PF** physical function, **HRQoL** health-related quality of life, **PhH** physical Health, **PsH** psychosocial health, **PF-LL** PF-lower limbs, **PF-HW** PF-hand and wrist, **PF-US** PF-upper segment

**Equal items–scale correlations (second Likert assumption)**

Pearson items–scale correlations corrected for overlap were roughly equivalent for items within a scale for 93% of the PF items, with the exception of PF item 15, and for 100% of the HRQoL items.

**Items internal consistency (third Likert assumption)**

Pearson items–scale correlations were ≥ 0.4 for 100% of items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency

Cronbach’s alpha was 0.92 for PF-LL, 0.91 for PF-HW, 0.88 for PF-US. Cronbach’s alpha was 0.83 for HRQoL PhH and 0.79 for HRQoL PsH.

Interscale correlation

The Pearson correlation of each item of the PF and the HRQoL with all items included in the remaining scales of the questionnaires was lower than the Cronbach’s alpha.

Test–retest reliability

Reliability was assessed in 47 JIA patients, by re-administering both versions (parent and child) of the JAMAR after a median of 3 days (0–7 days). The intraclass correlation coefficients (ICC) for the PF total score showed an almost perfect reproducibility (ICC = 0.97). The ICC for the HRQoL PhH showed an almost perfect reproducibility (ICC = 0.88) while the ICC for the HRQoL PsH showed a substantial reproducibility (ICC = 0.79).

Convergent validity

The Spearman correlation of the PF total score with the JIA core set of outcome variables ranged from 0.5 to 0.6 (median = 0.6). The PF total score best correlation was observed with the parent assessment of pain (r = 0.6, p < 0.001). For the HRQoL, the median correlation of the PhH with the JIA core set of outcome variables ranged from 0.4 to 0.7 (median = 0.6), whereas for the PsH ranged from 0.2 to 0.4 (median = 0.3). The PhH showed the best correlation with the parent’s assessment of pain (r = 0.7, p < 0.001) and the PsH with the parent global assessment of well-being (r = 0.5, p < 0.001). The median correlations between the pain VAS, the well-being VAS, and the disease activity VAS and the physician-centered and laboratory measures were 0.5 (0.3–0.6), 0.5 (0.4–0.5), 0.5 (0.4–0.6), respectively.

Discussion

In this study, the Argentinian Spanish version of the JAMAR was cross-culturally adapted from the original standard English version with two forward and two backward translations. According to the results of the validation analysis, the Argentinian Spanish parent and patient versions of the JAMAR possess satisfactory psychometric properties. Notably, there was no significant difference between the healthy subjects and their affected peers in the school-related problems variable. This finding indicates that children with JIA adapt well to the consequences of JIA, and have school performances comparable to those of their healthy peers. The PF total score proved to discriminate between the different JIA subtypes with children with undifferentiated arthritis having a higher degree of disability.

Psychometric performances were good for all domains of the JAMAR and the overall internal consistency was good for all the domains.

In the external validity evaluation, the Spearman’s correlations of the PF and HRQoL scores with JIA core set parameters ranged from moderate to strong.

The results obtained for the parent version of the JAMAR are very similar to those obtained for the child version, which suggests that children are equally reliable proxy reporters of their disease and health status as their parents.

The JAMAR is aimed to evaluate the side effects of medications and school attendance, which are other dimensions of daily life that were not previously considered by other HRQoL tools. This may provide useful information for intervention and follow-up in health care.

In conclusion, the Argentinian Spanish version of the JAMAR was found to have satisfactory psychometric properties and it is, thus, a reliable and valid tool for the multidimensional assessment of children with JIA.

Acknowledgements We thank all families who participated in the project, the team that prepared and reviewed the forward and backward translations, and all members of PRINTO in Argentina. A special thanks to Dr Marcela Alvarez, Dr Silvia Meiorin and Dr Laura Barzola for their important contribution within the study. We thank the staff of the PRINTO International Coordinating Centre in Genoa (Italy) and in particular Marco Garrone for the overall coordination of the translation process, Silvia Scala and Elisa Patrone for data collection and quality assurance, Luca Villa, Giuseppe Silvestri and Mariangela Rinaldi for the database development and management and the remaining PRINTO team for data entry. The Principal Investigator of the study was Prof. Angelo Ravelli, MD. The scientific coordinator and study methodologist was Nicolino Ruperto, MD, MPH. The project coordinators were Alessandro Consolaro, MD, PhD, Francesca Bovis, BSA. We thank also Prof. Alberto Martini, PRINTO Chairman. Funding was provided by the Istituto G. Gaslini, Genoa (Italy). Permission for use of JAMAR and its translations must be obtained in writing from PRINTO, Genoa, Italy. All JAMAR-related inquiries should be directed to at printo@gaslini.org. Permission for use of CHAQ and CHQ derived-material is granted through the scientific cooperation of the copyright holder ICORe of Woodside CA and HealthActCHQ Inc. of Boston, Massachusetts USA. All CHQ-related inquiries should be directed to licensing@healthactchq.com. All CHAQ-related inquiries should be directed to gsingh@stanford.edu.

Funding This study was funded and coordinated by Istituto Giannina Gaslini, Genoa, Italy.

Compliance with ethical standards

Conflict of interest Dr. Cuttica reports funding support from Istituto Giannina Gaslini, Genoa, Italy, for the data collection performed at his site within the EPOCA project. Dr. Ruperto has received grants from BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer, Sobi, during the conduct of the study and personal fees and speaker honorarium...
from Abbvie, Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Bio- 
gen Idec, Boehringer, Bristol Myers Squibb, Celgene, Eli-Lilly, EMD He- 
eron, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rph- 
harm, Roche, Sanofi, Servier and Takeda. Dr. Consolaro, Dr. Bovis, 
Dr. Britos, Dr. De Cunto, Dr. Espada, Dr. Fabi, Dr. Garay, Dr. Gomez 
Sosa, Dr. Katsicas and Dr. Russo have nothing to disclose.

Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti- 
tutional and/or national research committee and with the 1964 Helsinki 
Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual 
participants included in the study as per the requirement of the local 
ethical committee.

Open Access This article is distributed under the terms of the Crea- 
tive Commons Attribution 4.0 International License (http://creativeco 
mmons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.

References

1. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi 
B, Magni-Manzoni S et al (2011) A new approach to clinical care of 
juvenile idiopathic arthritis: the Juvenile Arthritis Multidimen-
sional Assessment Report. J Rheumatol 38(5):938–953

2. Ruperto N, Martini A (2011) Networking in paediatrics: the ex-
ample of the Paediatric Rheumatology International Trials Organisa-
tion (PRINTO). Arch Dis Child 96(6):596–601

3. Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, 
Garrone M et al (2012) Seeking insights into the EPidemiology, 
treatment and Outcome of Childhood Arthritis through a multi-
national collaborative effort: introduction of the EPOCA study. 
Pediatr Rheumatol Online J 10(1):39

4. Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone 
E et al (2018) Cross-cultural adaptation and psychometric evalu-
ation of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) in 54 languages across 52 countries: review of 
the general methodology. Rheumatol Int. https://doi.org/10.1007/ 
s00296-018-3944-1 (in this issue)

5. Petty RE, Southwood TR, Baun J, Bhettay E, Glass DN, Man-
ners P et al (1998) Revision of the proposed classification crite-
ria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 
25(10):1991–1994

6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Gold- 
enberg J et al (2004) International League of Associations for 
Rheumatology classification of juvenile idiopathic arthritis: sec-
ond revision, Edmonton, 2001. J Rheumatol 31(2):390–392

7. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, 
Pistorio A, Viola S et al (2007) Development and validation of 
a new short and simple measure of physical function for juvenile 
idiopathic arthritis. Arthritis Rheum 57(6):913–920

8. Lovell DJ, Howe S, Shear E, Hartner S, McGirr G, Schulte M et al 
(1989) Development of a disability measurement tool for juvenile 
rheumatoid arthritis. The juvenile arthritis functional assessment 
scale. Arthritis Rheum 32:1390–1395

9. Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M 
et al (1991) Development of a disability measurement tool for 
juvenile rheumatoid arthritis. The juvenile arthritis functional 
assessment report for children and their parents. Arthritis Rheum 
34:873–880

10. Singh G, Athreya BH, Fries JF, Goldsmith DP (1994) Measure-
ment of health status in children with juvenile rheumatoid arthri-
tis. Arthritis Rheum 37:1761–1769

11. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lat-
tanzi B et al (2010) Evaluation of 21-numbered circle and 10-cen- 
timeter horizontal line visual analag scales for physician and par-
ent subjective ratings in juvenile idiopathic arthritis. J Rheumatol 
37(7):1534–1541

12. Duffy CM, Arsenault L, Duffky KN, Paquin JD, Strawczyn-
ski H (1997) The Juvenile Arthritis Quality of Life Question-
naire—development of a new responsive index for juvenile rheu-
matoid arthritis and juvenile spondyloarthritides. J Rheumatol 
24(4):738–746

13. Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS 
(2002) The PedsQL(TM) in pediatric rheumatology—reliabil-
ity, validity, and responsiveness of the Pediatric Quality of Life 
Inventory(TM) generic core scales and rheumatology module. 
Arthritis Rheum 46(3):714–725

14. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual, 
1st edn. The Health Institute, New England Medical Center, ed. 
Boston, MA

15. Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio 
A, Solari N et al (2012) Parent and child acceptable symptom state 
in juvenile idiopathic arthritis. J Rheumatol 39(4):856–863

16. Nunnally JC (1978) Psychometric theory, 2nd edn. McGraw-Hill, 
New York, NY

17. Giannini EH, Ruperto N, Ravela A, Lovell DJ, Felson DT, Mar-
tini A (1997) Preliminary definition of improvement in juvenile 
arthritis. Arthritis Rheum 40(7):1202–1209

18. Ware JE Jr, Harris WJ, Gandek B, Rogers BW, Reese PR (1997) 
MAP-R for windows: multitrait/multi-item analysis program—
revised user’s guide. Version 1.0 ed. Health Assessment Lab, 
Boston, MA

Affiliations

Stella Maris Garay1 · Ruben Cuttica2 · Maria Martha Katsicas3 · Graciela Espada4 · Carmen De Cunto5 · Mariana Fabi1 · 
Jimena Gomez Sosa2 · Ricardo Russo3 · Maria de los Angeles Britos5 · Alessandro Consolaro6,7 · Francesca Bovis6 · 
Nicolino Ruperto6 · For the Paediatric Rheumatology International Trials Organisation (PRINTO)

Ruben Cuttica 
cutticarj@yahoo.com.ar

Maria Martha Katsicas 
mkkatsi@yahoo.com.ar

Graciela Espada 
gre-reumato-hnr@fibertel.com.ar

Carmen De Cunto 
carmen.decunto@hiba.org.ar
1 Hospital Sor María Ludovica, Servicio de Reumatologia, Unidad de Reumatologia, Calle 14 No 1631, 1900, La Plata, Argentina

2 Rheumatology Section, Hospital General de Ninos Pedro de Elizalde, Buenos Aires, Argentina

3 Servicio de Inmunologia/Reumatologia, Hospital de Pediatria Juan P. Garrahan, Buenos Aires, Argentina

4 Sección Reumatologia, Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina

5 Pediatrics, Rheumatology and Immunology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

6 Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy

7 Dipartimento di Pediatria, Università di Genova, Genoa, Italy